|
MA54555A
(fr)
|
2018-11-22 |
2021-09-29 |
Qilu Regor Therapeutics Inc |
Agonistes de glp-1r et leurs utilisations
|
|
EP3953344A4
(en)
|
2019-04-12 |
2023-08-09 |
Qilu Regor Therapeutics Inc. |
GLP-IR AGONISTS AND THEIR USES
|
|
TWI751585B
(zh)
|
2019-06-28 |
2022-01-01 |
美商美國禮來大藥廠 |
類升糖素肽1受體促效劑
|
|
EP4048664A1
(en)
|
2019-10-25 |
2022-08-31 |
Gilead Sciences, Inc. |
Glp-1r modulating compounds
|
|
CN114761395B
(zh)
*
|
2019-12-02 |
2024-11-15 |
现代药品株式会社 |
Glp-1受体激动剂
|
|
ES3016132T3
(en)
|
2020-01-29 |
2025-05-08 |
Gilead Sciences Inc |
Glp-1r modulating compounds
|
|
HRP20241159T1
(hr)
|
2020-02-07 |
2024-12-06 |
Gasherbrum Bio, Inc. |
Heterociklički agonisti za glp-1
|
|
IL296336A
(en)
*
|
2020-03-18 |
2022-11-01 |
Lg Chemical Ltd |
Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
|
|
TW202144340A
(zh)
*
|
2020-04-03 |
2021-12-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
|
|
TW202206429A
(zh)
|
2020-04-29 |
2022-02-16 |
美商迦舒布魯姆生物有限公司 |
雜環ｇｌｐ—１促效劑
|
|
JP2023537501A
(ja)
|
2020-08-06 |
2023-09-01 |
ガシャーブラム・バイオ・インコーポレイテッド |
ヘテロ環ｇｌｐ－１アゴニスト
|
|
EP4204415A4
(en)
|
2020-08-28 |
2025-03-26 |
Gasherbrum Bio, Inc. |
HETEROCYCLIC GLP-1 AGONISTS
|
|
CN116368140A
(zh)
|
2020-09-10 |
2023-06-30 |
加舒布鲁姆生物公司 |
杂环glp-1激动剂
|
|
EP4247804A1
(en)
|
2020-11-20 |
2023-09-27 |
Gilead Sciences, Inc. |
Polyheterocyclic glp-1 r modulating compounds
|
|
MX2023006186A
(es)
*
|
2020-11-27 |
2023-08-07 |
Shenzhen Salubris Pharm Co Ltd |
Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo.
|
|
WO2022192428A1
(en)
|
2021-03-11 |
2022-09-15 |
Gilead Sciences, Inc. |
Glp-1r modulating compounds
|
|
EP4304712A1
(en)
|
2021-03-11 |
2024-01-17 |
Gilead Sciences, Inc. |
Glp-1r modulating compounds
|
|
JP7772778B2
(ja)
|
2021-03-24 |
2025-11-18 |
塩野義製薬株式会社 |
縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
|
|
WO2022216094A1
(ko)
*
|
2021-04-08 |
2022-10-13 |
주식회사 엘지화학 |
Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
|
|
IL306110A
(en)
|
2021-04-21 |
2023-11-01 |
Gilead Sciences Inc |
Carboxy-benzimidazole glp-1r modulating compounds
|
|
TWI843104B
(zh)
|
2021-05-20 |
2024-05-21 |
美商美國禮來大藥廠 |
類升糖素肽1受體促效劑
|
|
IL309235A
(en)
*
|
2021-06-24 |
2024-02-01 |
Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd |
Glp-1 receptor agonist and composition and use thereof
|
|
CN113480534B
(zh)
*
|
2021-07-23 |
2022-05-13 |
广州必贝特医药股份有限公司 |
苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
|
|
WO2023029380A1
(zh)
|
2021-08-30 |
2023-03-09 |
杭州德睿智药科技有限公司 |
作为glp1r激动剂的新型芳醚取代杂环类化合物
|
|
US20240374587A1
(en)
|
2021-09-08 |
2024-11-14 |
Shionogi & Co., Ltd. |
Medicine for prevention and treatment of diseases linked to anti-obesity activity
|
|
PT4408840T
(pt)
|
2021-09-27 |
2025-10-07 |
Terns Pharmaceuticals Inc |
Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
|
|
WO2023057414A1
(en)
|
2021-10-05 |
2023-04-13 |
Astrazeneca Ab |
Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
|
|
US20250115612A1
(en)
|
2021-10-05 |
2025-04-10 |
Astrazeneca Ab |
Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators
|
|
MX2024004131A
(es)
|
2021-10-05 |
2024-04-22 |
Astrazeneca Ab |
Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1.
|
|
CN118401519A
(zh)
|
2021-10-25 |
2024-07-26 |
拓臻制药公司 |
作为glp-1r激动剂的化合物
|
|
WO2023111144A1
(en)
|
2021-12-16 |
2023-06-22 |
Astrazeneca Ab |
Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
|
|
US20250042882A1
(en)
|
2021-12-16 |
2025-02-06 |
Astrazeneca Ab |
Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
|
|
CN119095843A
(zh)
|
2022-02-23 |
2024-12-06 |
拓臻制药公司 |
作为glp-1r激动剂的化合物
|
|
US20250136584A1
(en)
*
|
2022-05-20 |
2025-05-01 |
Chengdu Di'ao Jiuhong Pharmaceutical Factory |
Benzimidazole Or Azabenzimidazole Compound, Preparation Method Therefor And Use Thereof
|
|
EP4562006A1
(en)
*
|
2022-07-27 |
2025-06-04 |
Carmot Therapeutics, Inc. |
N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
|
|
EP4592285A1
(en)
|
2022-09-22 |
2025-07-30 |
Shionogi & Co., Ltd. |
Fused ring compound having glp-1 receptor agonist effect
|
|
WO2024102625A1
(en)
|
2022-11-11 |
2024-05-16 |
Eli Lilly And Company |
Glucagon-like peptide 1 receptor agonists
|
|
KR20250085816A
(ko)
|
2022-11-16 |
2025-06-12 |
일라이 릴리 앤드 캄파니 |
글루카곤-유사 펩티드 1 수용체 효능제
|
|
WO2024125442A1
(zh)
*
|
2022-12-13 |
2024-06-20 |
杭州中美华东制药有限公司 |
Glp-1受体激动剂的新晶型和制备方法及其药物组合物和用途
|
|
CN120957993A
(zh)
|
2023-02-16 |
2025-11-14 |
加舒布鲁姆生物公司 |
杂环glp-1激动剂
|
|
EP4568664B1
(en)
|
2023-04-07 |
2026-04-01 |
Terns Pharmaceuticals, Inc. |
Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
|
|
CN120981457A
(zh)
|
2023-09-14 |
2025-11-18 |
歌礼制药(中国)有限公司 |
Glp-1r激动剂及其治疗方法
|
|
US20250157580A1
(en)
*
|
2023-11-13 |
2025-05-15 |
Aspen Neuroscience, Inc. |
Methods of predicting dopamine production capability of differentiated neuronal cells
|
|
TW202521534A
(zh)
|
2023-11-24 |
2025-06-01 |
香港商歌禮製藥(中國)有限公司 |
Glp-1r 激動劑及其治療方法
|
|
WO2025158275A1
(en)
|
2024-01-24 |
2025-07-31 |
Pfizer Inc. |
Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
|
|
TW202600132A
(zh)
|
2024-03-08 |
2026-01-01 |
美商安尼波那生物公司 |
用於治療肥胖症及提高減重之方法
|